Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 3/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23782930 | 0.90 | KDM4E (0.45) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL10286623 | 0.84 | BRD4 (0.39) | KDM4EBRD4ALDH1A1MAPTNPSR1 | |
| SCHEMBL18152970 | 0.77 | GABRA1 (0.35) | KDM4EALDH1A1MAPTGAA | |
| SCHEMBL23783013 | 0.76 | ALDH1A1 (0.34) | KDM4EALDH1A1MAPTHSD17B10 | |
| SCHEMBL10286620 | 0.73 | ALDH1A1 (0.39) | KDM4EBRD4ALDH1A1MAPTNPSR1 | |
| SCHEMBL20478507 | 0.72 | KDM4E (0.46) | KDM4EBRD4ALDH1A1MAPTNPSR1 | |
| SCHEMBL883080 | 0.71 | HSD17B10 (0.37) | KDM4EALDH1A1MAPTHPGDHSD17B10 | |
| SCHEMBL23783073 | 0.71 | KDM4E (0.54) | KDM4EBRD4ALDH1A1MAPTNPSR1 | |
| SCHEMBL10286587 | 0.69 | PLK1 (0.33) | KDM4EBRD4ALDH1A1MAPTHPGD | |
| SCHEMBL883077 | 0.69 | ALDH1A1 (0.42) | KDM4EBRD4ALDH1A1MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2023-05-11 | — | — | US | disclosed |
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2023-05-11 | — | — | US | disclosed |
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2023-05-11 | — | — | US | disclosed |
| WO-2021178780-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. (US) | 2021-09-10 | — | — | WO | disclosed |
| WO-2021178780-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. (US) | 2021-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, GDI2 | KDM4E 1401/4885BRD4 267/4885ALDH1A1 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.